InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

Posted: September 25, 2022 at 2:04 am

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.

Originally posted here:
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

Related Posts